Analysis of price advantage and therapeutic effect of cimepilimab

Cemiplimab (Cemiplimab) is a new immune checkpoint inhibitor with outstanding clinical effects in advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma as well as certain types of non-small cell lung cancer (NSCLC). As a fully humanized IgG4 monoclonal antibody targeting the PD-1 (programmed death protein 1) pathway, cimepilimab can effectively identify and eliminate cancer cells by activating T cell-mediated immune responses, thereby prolonging the progression-free survival and overall survival of patients. Its treatment mechanism is similar to pembrolizumab (Keytruda) and nivolumab (Opdivo), but may have better efficacy in certain populations. For example, in a clinical trial for patients with locally advanced CSCC, cimepilimab achieved an objective response rate (ORR) of 44% and a complete response rate of 13%, showing good therapeutic prospects.

However, in terms of price, cimipilimab is not currently on the market in mainland China, nor is it included in the national medical insurance directory. Therefore, patients who need to import the drug through special channels will have a relatively heavy financial burden. According to overseas market data, its commonly used specification is 350mg/7mL. The market price of each bottle may vary from RMB 40,000 to RMB 100,000 due to regional and exchange rate changes. Since there are no generic drugs available, patients have to rely on the brand-name drugs, which further limits their popularity. In contrast, some PD-1 drugs that have been included in medical insurance, such as sintilimab, tislelizumab and other domestic products, have more advantages in terms of price and accessibility. Therefore, when choosing an immunotherapy regimen, clinicians usually consider the patient's condition, genetic mutation status, previous treatment, and financial affordability.

Despite its high price, cimepilimab has been approved by the FDA and EMA abroad and has been included in corresponding treatment guidelines, indicating that its safety and efficacy have been recognized by authoritative institutions.

Reference materials:https://www.libtayohcp.com/